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Abstract
Background: Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response
mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ
dysfunction. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery.
CytoSorb® (Cytosorbents, NJ, USA) is a recent device designed to remove cytokine from the blood using
haemoadsorption (HA). This trial aims to evaluate the potential of CytoSorb® to decrease peri-operative cytokine
levels in cardiac surgery.
Methods: We have conducted a single-centre pilot randomized controlled trial in 30 patients undergoing
elective cardiac surgery and deemed at risk of complications. Patients were randomly allocated to either standard
of care (n = 15) or CytoSorb® HA (n = 15) during cardiopulmonary bypass (CPB). Our primary outcome was the
difference between the two groups in cytokines levels (IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, TNF-α, IFN-γ, MCP-1)
measured at anaesthesia induction, at the end of CPB, as well as 6 and 24 h post-CPB initiation. In a consecutive
subgroup of patients (10 in HA group, 11 in control group), we performed cross-adsorber as well as serial
measurements of coagulation factors’ activity (antithrombin, von Willebrand factor, factor II, V, VIII, IX, XI, and XII).
Results: Both groups were similar in terms of baseline and peri-operative characteristics. CytoSorb® HA during
CPB was not associated with an increased incidence of adverse event. The procedure did not result in significant
coagulation factors’ adsorption but only some signs of coagulation activation. However, the intervention was
associated neither with a decrease in pro- or anti-inflammatory cytokine levels nor with any improvement in
relevant clinical outcomes.
Conclusions: CytoSorb® HA during CPB was not associated with a decrease in pro- or anti-inflammatory
cytokines nor with an improvement in relevant clinical outcomes. The procedure was feasible and safe. Further
studies should evaluate the efficacy of CytoSorb® HA in other clinical contexts.
Trial registration: ClinicalTrials.gov NCT02775123. Registered 17 May 2016.
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Background
Cardio-pulmonary bypass (CPB) is routinely used
throughout the world during open-heart surgery. This
procedure is associated with a complex inflammatory
response through the activation of both coagulation
and alternative pathway of the complement system.
Numerous inflammatory molecules (C3a, C5a, hista-
mine, IL-6, IL-8, TNFα) are released and activate cel-
lular response leading to systemic inflammation,
increased vascular permeability and thrombosis [1–4].
When severe, this phenomenon might lead to sys-
temic hypotension and organ dysfunction, a situation
referred to as “post-pump syndrome” [4]. Given the as-
sociation between elevated pro-inflammatory cytokine
levels and adverse clinical outcomes (post-operative acute
kidney injury (AKI) [5], decreased systemic vascular resist-
ance [6] and reduced lung function [7]), it has been postu-
lated that extra-corporeal removal of cytokines could
improve outcomes.
CytoSorb® (CytoSorbents Corporation, Monmouth
Junction, NJ, USA) is a recent haemoadsorption (HA)
device designed to remove cytokines from the blood.
CytoSorb® cartridges contain biocompatible sorbent poly-
styrene divinylbenzene beads coated with polyvinylpyrroli-
done, capable of removing middle molecular weight
molecules using a combination of hydrophobic interac-
tions and size exclusion [8–11]. These cartridges can eas-
ily be inserted in a cardio-pulmonary bypass circuit.
To date, little is known about CytoSorb®’s efficacy dur-
ing cardiac surgery [9]. Small case-control series have
suggested improved clinical outcomes associated with
CytoSorb® HA during heart transplantation [12], surgical
management of acute infective endocarditis [13] or in
patients with severe post-CPB systemic inflammation re-
sponse syndrome [14]. A single pilot randomized con-
trolled trial has compared intra-operative CytoSorb® HA
with standard CPB in 32 patients undergoing elective
cardiac surgery [15]. In this trial, in patients with low to
medium risk of complications, the procedure was associ-
ated neither with a decrease in peri-operative cytokine
levels nor with an improvement in clinical outcomes.
We have therefore designed a pilot randomized con-
trolled trial to evaluate the potential of CytoSorb® HA to
decrease peri-operative cytokines levels in patients at
high risk of post-operative complications.
Methods
Study design
This prospective single-centre randomized controlled
trial took place in the Centre Hospitalier Universitaire
Vaudois (CHUV), Lausanne, Switzerland, between May
2016 and January 2018. The target population included
patients planned for elective cardiac surgery with ex-
pected long CPB duration and deemed at high risk of
post-operative complications. The study protocol was
approved by the Ethics Committee Vaud (2015-00010)
and registered at ClinicalTrials.gov (NCT02775123).
Inclusion and exclusion criteria
To be eligible to enter the study, patients had to fulfil at
least one of the following inclusion criteria: age > 75
years, double valve replacement, complex surgery with
expected CPB duration > 120 min, redo cardiac surgery,
pre-operative chronic renal failure (glomerular filtration
rate < 30 ml/min) or chronic heart failure (< 40% left
ventricular ejection fraction).
Exclusion criteria were end-stage renal disease (dialysis
dependence), active infectious endocarditis, emergency
or off-pump procedure, receipt of non-steroidal
anti-inflammatory medication (except for low-dose as-
pirin) or corticosteroids within 7 days or enrolment in
another conflicting study. Eligible patients were
approached, and written informed consent was obtained
prior to randomization.
Randomization
Randomization sequence was created using the Excel
(Microsoft, Redmond, USA) Rand () function with a 1:1
ratio and permuted blocks of random sizes (1–5). Allo-
cation information was stored within sealed opaque and
numbered envelopes.
Blinding
Patients, surgical, anaesthetic and ICU teams as well as la-
boratory staff were all blinded regarding group allocation.
Only the perfusionist managing the CPB and a
co-investigator were aware of the patient’s allocation. All
reasonable efforts were made to conceal the device (or ab-
sence of) from the sight of anaesthesiologists and surgeons;
however, no sham device was used for control cases.
Primary outcome
Our primary outcome was the change in blood levels of
key cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10,
IFN-γ, MCP-1 and TNFα) in the peri-operative period
according to whether or not CytoSorb® was inserted in
the CPB. Such cytokines were measured in both groups
after induction of anaesthesia (T0), at the end of CPB
(after protamine administration; T2), 6 h after CPB initi-
ation (T3) and 24 h after CPB initiation (T4).
Secondary outcomes
Safety The impact of CytoSorb® HA on coagulation fac-
tors’ activity [antithrombin (AT), von Willebrand factor
(vWF), factors II, V, VIII, IX, XI and XII] was assessed
through measurements performed at the aforementioned
time points in a subset of 21 consecutive patients (HA;
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n = 10, control; n = 11). For patients allocated to the HA
group, an additional measure was performed at T1 (60
min after CPB initiation) to evaluate cross-adsorber co-
agulation factors’ clearance. For this measure, simultan-
eous samples were collected from the access (venous)
line (pre-CPB) and the return (arterial) line (post-CPB).
Baseline and perioperative characteristics as well as their
outcomes of patients included in this sub-study are pre-
sented in Additional file 1: Tables S1 and S2.
Adverse events (AE) occurring within 28 days of
randomization were systematically collected for each pa-
tient and assessed for potential association with the
intervention. A serious adverse event was defined as any
untoward medical occurrence that results in death, is life
threatening, required prolonged hospitalization, results
in persistent or significant disability or requires interven-
tion to prevent impairment or damage.
Efficacy In addition to our primary outcome measures,
the following clinical outcomes were assessed: vasopres-
sor and inotropic support (need for any vasoconstrictor
or inotrope) within 24 h of ICU admission, need for any
mechanical assistance (IABP, ECMO), mechanical venti-
lation duration, fluid balance, incidence of AKI (accord-
ing to KDIGO criteria [16]), need for post-operative
renal replacement therapy and ICU length of stay.
Data collection
Baseline pre-operative characteristics (age, sex, body
weight and chronic diseases), chronic medications
(aspirin, angiotensin-converting enzyme inhibitors and
angiotensin II receptors blockers), routine laboratory
values and data relevant to the undertaken surgical pro-
cedure (type, CPB characteristics and fluid balance) were
collected. To be considered, pre-operative values had to
be obtained within 24 h of the procedure and discharge
values had to be the latest obtained before discharge.
Post-operative values for haemoglobin, platelets, aPTT
and PT were obtained on ICU admission. Outcomes’
data were collected at ICU and hospital discharge.
Procedure
General anaesthesia was induced with propofol, sufenta-
nil and rocuronium. It was maintained with sufentanil
boluses, sevoflurane before and after bypass and propo-
fol during bypass. Tranexamic acid was administered as
a 10-mg/kg bolus on anaesthesia induction followed by a
1-mg/kg/h infusion throughout CPB. Heparinization was
initiated with a 300-UI/kg bolus and titrated according
to haemostasis management system (HMS) Plus
(Medtronic, Minneapolis, USA). An ACT > 400 s was re-
quired to initiate CPB. At the end of the procedure, hep-
arin was reversed with protamine titrated according to
HMS calculations.
The CPB included a Capiox® FX25 (Terumo, Tokyo,
Japan) or Quadrox-i® (Maquet, Rastatt, Germany) mem-
brane oxygenator and a heater-cooler system (Livanova,
London, England). A roller or centrifugal pump was
used according to the perfusionist’s preferences. The cir-
cuit was primed with heparin and Plasmalyte-A® (Baxter,
Deerfield, USA). If deemed necessary, a haemofilter
(haemoconcentrator, Sorin) was used. A non-pulsatile
flow at 2.4 L/m2/min was maintained with a target mean
arterial pressure between 60 and 80 mmHg. For this pur-
pose, phenylephrine was administrated if deemed neces-
sary. Myocardial protection was achieved using either St.
Thomas® (Bichsel Laboratorium, Interlaken, Switzerland)
or Custodiol® HTK (Sandor Medicaids, Hyderabad,
India) cardioplegia solution, according to the surgeon’s
preferences. Transesophageal echocardiography (TEE)
was performed throughout the procedure.
For patients allocated to the HA group, a CytoSorb®
cartridge was purged with NaCl 0.9% and integrated into
the CPB circuit. The device was inserted in a side arm
connected to the outflow line (high-pressure section)
and the venous reservoir, prior to the oxygenator. No
flow monitoring was conducted.
Blood sampling
Blood samples were drawn in ethylene-diamine-tetra-acetic
acid (EDTA) (cytokine analyses) or 0.106M sodium citrate
(coagulation factors) tubes. All samples were collected
using standard hygiene precautions from patients’ arterial
line or within the CPB circuit (T1 pre and post-adsorber
measurements).
EDTA samples were centrifuged at 1500g at 4 °C for
10 min. Three aliquots of 100-μl plasma were prepared
and stored at − 80 °C. Cytokine quantification was per-
formed by the Mouse Metabolic Evaluation Facility
(MEF), University of Lausanne, using Human Cytokine
Magnetic 10-Plex Panel on the Luminex® Platform
(Thermo Fischer Scientific®, Waltham, USA) [17].
Detection thresholds for cytokines are presented in
Additional file 1: Table S3.
Citrate samples were centrifuged at 1500g for 15 min.
Plasma samples were then preserved at − 20 °C. For ana-
lyses, samples were thawed at 37 °C in 10min. Residual
heparin activity was reversed with protamine according
to measured anti-Xa activity (1 UI per UI/ml anti-XA ac-
tivity). Factor II, V, VIII, IX, XI and XII activity was mea-
sured using a one-stage assay method. AT and vWF
activity were assessed using a chromogenic method
(respectively Berichrom® Antithrombin III, and INNO-
VANCE® vWFAc). Coagulation factors’ activity measure-
ments were all performed at our central coagulation
laboratory, using Sysmex® CS-5100 System (Siemens
Healthineers, Erlangen, Germany).
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Statistical analysis
Based on previous literature [18], we calculated that, in
order to be able to demonstrate a 25% change in serum
IL-6 concentration, assuming a mean value of 200 pg/ml
and a standard deviation of 50 pg/ml, we would need to
recruit 15 patients in each arm to achieve a power of
80% with statistical significance set at 0.05.
A continuous variable is reported using mean and
standard deviation (SD) or median and interquartile
range (IQR) according to data distribution. Categorical
variables are described using absolute frequencies and
relative percentages.
For baseline characteristics and clinical outcomes com-
parisons, differences between groups were analysed by
using t test or Wilcoxon signed-rank test for continuous
variables and Fisher’s exact test for categorical variables. A
p value < 0.05 was considered statistically significant.
For cytokine level comparisons, since cytokine levels
were non-normally distributed, they are reported as me-
dian (IQR). The Mann-Whitney U test was performed
for inter-group comparisons at each time point. Effect of
time within each group was assessed using the
Kruskal-Wallis one-way analysis of variance. A p value
< 0.05 was considered statistically significant.
For coagulation factors’ analyses, comparisons of pre-
and post-adsorber measurements of coagulation factors’
activity were performed using paired Student’s t tests.
The effect of HA on coagulation factors throughout
study time points was assessed by repeated measures’
analysis of variance (ANOVA) and analysis of covariance
(ANCOVA) models. Final ANCOVA models included
FFP administration, fluid balance and baseline value.
Statistical threshold was determined as p = 0.016 after
Bonferroni correction.
All analyses were performed using IBM SPSS Statis-
tics (25).
Results
During the study period, 569 patients underwent elective
cardiac surgery with CPB in our institution. Of those,
211 (37%) were considered at high risk of post-operative
complications and were potentially eligible to participate
in this study. Altogether, 33 patients were enrolled in the
trial. Of those, three were excluded: one withdrew his
consent prior to the intervention, one patient had a last
minute change of the surgical plan and one had an
intra-operative unexpected discovery of an infective
endocarditis. Hence, 15 patients were assigned to the
control group and 15 to the HA group.
Baseline demographics and peri-operative characteristics
Baseline and peri-operative characteristics of included
patients are detailed in Table 1. There was no difference
between the two groups in terms of baseline or
peri-operative characteristics except for a lower protam-
ine/heparin ratio in the HA group (p = 0.02). Median
CPB duration was 142.5 (114.3–200) min.
Primary outcome: cytokine levels
Cytokines’ measurements throughout study time points are
presented in Fig. 1. Il-6 and Il-4 baseline serum levels were
higher in the HA group. Compared to baseline values, the
surgical procedure was associated with an increase in IL-6
(peak level 6 h after CPB initiation, T3), MCP-1 and IL-10
levels (peak level at the end of CPB, T2). On the other hand,
it was associated with a decrease in IL-1α, IL-1β, IL-2, IL-4,
IL-5 and IFN-γ levels (nadir at T2 and T3). No change in
TNF-α levels was observed until T4. There was no statisti-
cally significant difference between the two groups in serum
levels of any of the cytokines of interest at any time point.
Clinical outcomes
Clinical outcomes are reported in Table 2. There was no
significant difference between the two groups in the use
of vasoconstricting drugs (p = 1.0), mean noradrenaline
dose on the first post-operative day (p = 0.87), use of any
post-operative inotrope (p = 0.68), duration of mechan-
ical ventilation (p = 0.31), incidence of AKI (p = 1.0),
ICU length of stay (p = 1.0) and ICU and hospital mor-
tality (both p = 1.0).
Safety
Coagulation factors
Cross-adsorber clearance Pre- and post-adsorber mea-
surements of coagulation factors’ levels are reported in
Fig. 2. There was no statistically significant difference in
factors V, VIII, IX, XI and XII nor in vWF activity be-
tween pre- and post-adsorber measurements. A small
but statistically significant decrease in AT and FII was
observed (resp. from 70.4 ± 15.3 to 66.6 ± 16.5, p = 0.006,
and 61.6 ± 16.2 to 57.3 ± 16.3, p = 0.03).
Time comparisons The evolution of coagulation factors
throughout the study period is presented in Fig. 3.
Unadjusted analyses revealed a difference in vWF and
factor II activities (p = 0.04 and 0.005); however, after ad-
justment for baseline values, FFP and fluid balance, only
factor II activity remained statistically significantly lower
after the end of CPB in the HA group (p = 0.02). In
addition, adjusted analyses revealed a lower factor XII
activity at the end of CPB in the HA group (p = 0.005).
Classic haematological parameters Pre- and
post-operative values for haemoglobin, thrombocytes,
aPTT and INR are presented in Additional file 1: Table
S4. There was no statistically significant difference be-
tween the two groups for these parameters.
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Table 1 Baseline and peri-operative characteristics*
Control
(N = 15)
CytoSorb
(N = 15)
Pre-operative characteristics
Median age—(IQR) years 69 (49–80) 67 (44–76)
Male sex—no. (%) 11 (73.3) 13 (86.7)
Median body weight—(IQR) kg 80 (76–94) 86 (73–91)
Median left ventricular ejection fraction—(IQR) % 60 (35–65) 53 (43–57)
Median Euroscore II—(IQR) % 5.1 (2.1–7.2) 3.0 (2.2–9.1)
Coexisting conditions—no. (%)
Chronic kidney disease† 4 (26.7) 3 (20)
Chronic heart failure ‡ 5 (33.3) 2 (13.3)
Hypertension± 9 (60.0) 10 (66.7)
Diabetes± 2 (13.3) 4 (26.7)
Cerebro-vascular disease∞ 1 (6.7) 0 (0)
Peripheral vascular disease 4 (26.7) 3 (42.9)
Smoking 6 (40) 7 (46.7)
Chronic obstructive pulmonary disease£ 2 (13.3) 1 (6.7)
Mean pre-op haemoglobin level—(SD) g/L 134 (19) 132 (19)
Mean pre-op creatinine level—(SD) μmol/L 104 (34) 89 (22)
Intraoperative characteristics
Type of procedure—no. (%)
CABG or single valve replacement 2 (13.3) 2 (13.3)
Double valve replacement 1 (6.7) 0 (6.7)
CABG and valve replacement 6 (40) 3 (20)
Ascending aortic procedure 5 (33.3) 5 (33.3)
Others 1 (6.7) 5 (33.3)
Cardio-pulmonary bypass characteristics
Median bypass duration—(IQR) min 138 (87–207) 145 (130–183)
Median cross-clamp duration (IQR) min 115 (68–159) 122 (97–146)
Centrifugal pump—no. (%) 5 (33.3) 4 (26.7)
Ultrafiltration—no. (%) 9 (45) 11 (73.3)
Median ultrafiltration volume—(IQR) mL 1000 (0–2500) 1500 (0–2000)
Modified ultrafiltration—no. (%) 2 (13.3) 2 (13.3)
Modified ultrafiltration volume—(IQR) mL 0 (0–0) 0 (0–0)
Fluid Balance at T2—(IQR) mL 2840 (2105–3643) 3125 (2480–3946)
Fluid Balance at T3—(IQR) mL 4371 (2921–5181) 4324 (3556–5460)
Fluid Balance at T4—(IQR) mL 6551 (5139–7301) 6702 (5657–7332)
Median SAPS II on ICU admission (IQR) 37.0 (34.0–49.0) 43.0 (21.0–48.0)
CABG coronary artery bypass grafting, IQR interquartile range, SAPS II simplified acute physiology score, SD standard deviation, ICU intensive care unit
*There were no significant differences between the groups with regard to any pre-operative or intra-operative characteristics (all p values > 0.05)
†Chronic kidney disease was defined by a creatinine clearance < 30 ml/min
‡Chronic heart failure was defined by a left ventricular ejection fraction < 40%
±Hypertension and diabetes were defined as the need for a disease specific medication
∞Cerebro-vascular disease was defined by a history of stroke or transient ischemic attack
£COPD was defined by a documented FEV1/FVC < 0.7 according to the GOLD criteria
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Fig. 1 (See legend on next page.)
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Other adverse events
As summarized in Table 3 (and detailed in
Additional file 1: Table S5), 53 AE were reported during
the study: 30 (10 patients) in the control group and 23
(11 patients) in the CytoSorb group (p = 1.0 for number
of patients). Of those, 25 were considered as serious AE:
12 (eight patients) in the control group and 13 (eight
patients) in the CytoSorb group (p = 1.0 for number of
patients). Fatal AE were reported for two (13.3%)
patients in the control group and one (6.7%) in the
CytoSorb group (p = 1.0). Cause of death is detailed in
Additional file 1: Table S6. Categories of encountered
AE and respective distribution between the two groups
are presented in Table 3. No obvious AE appeared to be
directly attributable to the CytoSorb® device.
Discussion
Key findings
We performed a single-centre pilot randomized con-
trolled trial on 30 patients undergoing elective cardiac
surgery and deemed at high risk of peri-operative com-
plications. In those patients, we evaluated the safety and
efficacy of CytoSorb® haemoadsorption during CPB in
comparison with standard management. We found that
the procedure, as described, appeared safe and feasible
as no immediate or delayed complication attributable to
the device was observed. A thorough investigation of co-
agulation parameters did not demonstrate any relevant
alteration of coagulation factors or thrombocytes levels
associated with the procedure. However, the intervention
was not associated with a decrease in key cytokine levels.
Similarly, although the study was not powered to
examine these outcomes, it was not associated with a
difference in terms of need for vasoconstrictors,
post-operative AKI or need for RRT, ICU length of stay
and in-hospital mortality.
Comparison with previous studies
Our main result is consistent with findings from a previ-
ous and similar RCT conducted in Austria by Bernardi
et al. [15]. In this trial, patients undergoing elective car-
diac surgery with an expected CPB duration of more
than 120 min were randomly allocated to either
CytoSorb® HA or control group. After the exclusion of
five patients, 32 were included in the main analysis (16
in each group). The authors did not find any difference
in peri-operative levels of IL-6, IL-10, IL-18, IL-1β and
TNF-α and HMGβ1 except for a longer decay for IL-10
in the CytoSorb® group.
Patients included in both trials appear to be compar-
able in terms of age, EuroSCORE and comorbidities. Al-
though arguably patients included in our study
underwent more complex procedures (aortic proce-
dures), this did not translate in a longer CPB duration
(138/145 min versus 170/191 min). Hence, both studies
have evaluated CytoSorb® HA in a collective of patients
at high risk of complications.
We have analysed a different panel of cytokines, in-
cluding pro-inflammatory IL-1α, IL-1β, IL-6, IFNγ,
TNFα and MCP-1, as well as anti-inflammatory, IL-4,
IL-5 and IL-10. However, similar to Bernardi et al., we
failed to demonstrate any effect of CytoSorb® HA on
these cytokines. Of note, we did not observe higher
IL-10 levels in the CytoSorb group. The absence of effi-
cacy observed in the Austrian trial [15] is therefore con-
firmed by our data. In addition, consistent with the
observation made, we have observed large inter-patient
variability.
The observed lack of efficacy of the therapy might
be explained by the low inflammatory response ob-
served in patients included in both trials. Indeed, in
an observational study, intra-operative CytoSorb HA
was associated with a decreased requirement for
post-operative vasoconstrictors in 39 patients with in-
fective endocarditis compared with historical controls
[13]. However, in these patients, peak (post-operative)
IL-6 levels were around 400 mg/ml, a value much
higher than those observed in our trial (median peak
IL-6 levels (2 h post-CPB) 120.8 [49.0–160.8] pg/ml in
the HA group and 118.7 [68.4–255.9] pg/ml in the
control group).
IL-6, IL-10 and MCP-1 have exhibited the classically
reported pattern of an increase associated with the CPB
followed by slow return to baseline. However, less com-
monly reported cytokines (IL-1 α, IL-1β, IL-4, IL-5) have
exhibited a different pattern. In both groups, CPB was
associated with a decrease in the plasma level of these
cytokines. This pattern is an unexpected finding of un-
known significance. It could be partly related to haemo-
dilution but at a minimum suggests against a significant
activation of their signalling systems induced by CPB.
To the best of our knowledge, this is the first trial
evaluating the consequences of CytoSorb® HA on coagu-
lation parameters. Several studies have reported a trend
(See figure on previous page.)
Fig. 1 Median pro-inflammatory cytokine measurements throughout the study period. Whiskers indicate IQR. T0, induction of anaesthesia; T2, end of
cardio-pulmonary bypass; T3, 6 h after the end of cardio-pulmonary bypass; and T4, 24 h after the end of CPB. IL interleukin; IFN-γ, interferon-gamma;
MCP-1, monocyte chemoattractant protein-1; TNF-α, tumour necrosis factor-alpha. Inter-group comparisons performed using the Mann-Whitney U test
comparisons at each time point. Effect of time within each group was significant (Kruskal-Wallis one-way analysis of variance) for all measurements
(p < 0.05) except for IFN-γ in the control group (p = 0.09) and IL-2 in the control (p = 0.232)
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for thrombocytopenia [19] during HA. We have not ob-
served such association.
Strengths and limitations
This study has several strengths. Despite the small sam-
ple size, baseline characteristics were well balanced be-
tween the two groups of patients. We have examined a
large panel of pro- and anti-inflammatory cytokines at
different relevant time points. In addition, we have con-
ducted a thorough evaluation of CytoSorb® effect on sev-
eral coagulation parameters. These analyses involved
cross-adsorber clearance measurement, coagulation fac-
tors’ levels throughout relevant time points and conven-
tional haematological evaluation. To the best of our
knowledge, our study is the first to provide such a broad
assessment during CytoSorb® HA.
Some limitations are however present. First, it is a
monocentric pilot study, on a rather small collective
of patients. Our results are therefore subject to
Table 2 Clinical outcomes*
Control
(N = 15)
CytoSorb
(N = 15)
Outcome
Re-operation within 48 h—no. (%) 1 (6.7) 0 (0)
Post-operative extracorporeal membrane oxygenation—no. (%) 0 (0) 1 (6.7)
Post-operative intra-aortic balloon pump—no. (%) 0 (0) 0 (0)
Vasoconstrictors
Need for any vasoconstrictor—no. (%) 13 (86.7) 14 (93.3)
Median noradrenaline dose post-operative day 1—(IQR) μg/min 4.8 (2.0–13.7) 5.6 (1.5–6.8)
Median noradrenaline dose post-operative ICU stay—(IQR) μg/min 4.3 (2.0–7.8) 4.7 (1.5–7.1)
Inotropes
Need for any inotrope—no. (%) 12 (80.0) 10 (66.7)
Median dobutamine dose post-operative day 1—(IQR) μg/min 0 (0) 0 (0–162)
Median dobutamine dose post-operative ICU Stay—(IQR) μg/min 0 (0–103) 0 (0–141)
Fluid balance at 24 h ICU—(IQR) ml 2240 (400–3589) 3000 (2000–4250)
Diuresis 24 h ICU—(IQR) ml 1125 (895–1700) 1495 (970–1930)
Mechanical ventilation—(IQR) hours 8 (2–102) 5 (0–16)
Acute kidney injury—no. (%)† 4 (26.7) 4 (26.7)
Post-operative need for renal replacement therapy—no. (%) 1 (6.7) 0 (0)
Renal replacement therapy dependence on hospital discharge—no. (%) 1 (6.7) 0 (0)
Serum creatinine on ICU discharge—(IQR) μmol/l 78 (65–126) 73 (68–103)
Serum creatinine on hospital discharge—(IQR) μmol/l 87 (72–120) 78 (68–97)
ICU length of stay—(IQR) days 1.0 (0.9–8.9) 1.8 (0.9–2.0)
Hospital length of stay—(IQR) days 12.0 (11.0–17.0) 12.5 (6.0–19.0)
ICU readmission—no. (%) 1 (7.7) 2 (13.3)
ICU mortality—no. (%) 2 (13.3) 1 (6.7)
Hospital mortality—no. (%) 2 (13.3) 1 (6.7)
ICU intensive care unit, IQR interquartile range, SD standard deviation
*There were no significant differences between the groups with regard to any pre-operative or intra-operative characteristics (all p values > 0.05)
†Acute kidney injury was defined as per the Kidney Disease: Improving Global Outcomes (KDIGO) classification
Fig. 2 Coagulation factors cross-adsorber clearance. Pre- and post-
adsorber samples were collected 60min after the initiation of CPB
(T1). AT, antithrombin; F, factor; vWF, von Willebrand factor.
Comparisons performed using paired Student’s t tests
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selection bias, and the external validity of our results
can be limited. However, our findings are largely con-
sistent with those obtained in a similar study but
conducted in another health care system and another
country.
Second, the duration of CytoSorb® HA was restricted
to the CPB duration, which might not be sufficient to
demonstrate efficacy. Indeed, cytokine release requires
complex intracellular signalling mechanisms before they
can be upregulated, expressed and secreted. The device
Fig. 3 Coagulation factors measurements throughout the study period. T0, induction of anaesthesia; T2, end of CPB; T3, 6 h after the end of CPB;
and T4, 24 h after the end of CPB. AT, antithrombin; F, factor; vWF, von Willebrand factor. The effect of HA on coagulation factors throughout
study time points was assessed by repeated measures’ analysis of variance (ANOVA) and analysis of covariance (ANCOVA) models. Final ANCOVA
models included FFP administration, fluid balance and baseline value. Statistical threshold was determined as p = 0.016 after Bonferroni correction
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insertion might have been too early relative to
CPB-induced immune response and the duration of the
therapy insufficient. However, insertion of the cartridge
during CPB is a pragmatic, easy and potentially
generalizable practice with minimal manipulations and
risks to the patient. Longer therapy would require inser-
tion of a double-lumen catheter and prolonged anticoa-
gulation, which might not be desirable.
Third, although we have selected patients at risk of
post-operative complications, the actual rate of such com-
plications was relatively low and most patients required lit-
tle ICU support. This might be consistent with the
relatively low cytokine levels. A positive effect of the device
on patients with higher inflammatory response and higher
incidence of post-pump syndrome cannot be ruled out.
Finally, the utilization of modified ultrafiltration in
some patients might have attenuated the effect of the
device [20]. However, such utilization was limited to two
patients in each group. Post hoc analyses performed
after exclusion of these patients confirmed main results.
Study implications
Our study shows that, even in patients at high risk of
complications, as defined by clinical criteria, CytoSorb®
HA, during CPB is not associated with a significant de-
crease in cytokine levels. This absence of effect might be
related to a low inflammatory response, to an insuffi-
cient therapy duration or to an inadequate timing rela-
tive to pro-inflammatory cytokine production. Although
an effect in patients with higher rate of post-pump syn-
drome and higher inflammatory response cannot be
ruled out, CytoSorb® HA is not likely to be beneficial in
the vast majority of elective cardiac procedures with low
to moderate inflammatory responses. Together with the
trial from Bernardi et al. [15], and despite small sample
sizes, we can now conclude that routine application of
CytoSorb® HA seems not to be justified for elective car-
diac procedures. Indeed, given the absence of effect in
two well-conducted RCT in patients with high risk of
complications and prolonged CPB but nevertheless low
cytokine levels, it is highly unlikely that a larger or
multi-centre trial would demonstrate a benefit.
Further studies are required to evaluate its potential in
particular situations perhaps associated with higher cyto-
kine levels such as emergency procedures, acute infec-
tious endocarditis or heart transplantation as suggested
by observational studies [12, 13]. Post-operative use of
CytoSorb might also need to be evaluated [20]. The ob-
served heterogeneity of peri-operative measurements
might suggest that some particular patients could benefit
from the therapy. Hence, further studies might attempt
to include a point-of-care evaluation of cytokine levels
to enrich study population and restrict the intervention
to patients with elevated cytokine levels.
On the other hand, our trial has provided important
safety data in particular regarding the coagulation sys-
tem. The absence of significant alteration of the coagula-
tion system during the therapy is of major interest. The
Table 3 Adverse events and serious adverse events
Control
(n = 15)
CytoSorb
(n = 15)
p value
Total adverse events 30 23
Fatal adverse events 2 1
Patients with fatal adverse event—no. (%) 2 (13.3) 1 (6.7) 1.00
Patients with severe non-fatal adverse event—no. (%) 8 (53.3) 8 (53.3) 1.00
Patients with at least 1 adverse event—no. (%) 10 (66.7) 11 (73.3) 1.00
Adverse events categories
Respiratory—no. (%) 0 (0) 2 (13.3) 0.48
Cardiogenic shock—no. (%) 0 (0) 1 (6.7) 1.00
Haemorrhagic shock—no. (%) 0 (0) 1 (6.7) 1.00
Distributive shock—no. (%) 2 (13.3) 1 (6.7) 1.00
Arrhythmias—no. (%) 8 (53.3) 5 (33.3) 0.46
Surgical complications—no. (%) 4 (26.7) 4 (26.7) 1.00
Infection—no. (%) 4 (26.7) 1 (6.7) 0.33
Acute liver failure—no. (%) 0 (0) 1 (6.7) 1.00
Acute kidney injury—no. (%) 4 (26.7) 4 (26.7) 1.00
Neurological AE (including stroke)—no. (%) 3 (20.0) 2 (13.3) 1.00
Electrolyte disorders—no. (%) 1 (6.7) 0 (0) 1.00
All adverse events documented in the first 28 days following the randomisation were recorded. All patients who died were analysed and classified as fatal serious
events. Patients were counted once for each event category even if they had multiple events in that category. Comparisons were made by Fisher’s exact test
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small but significant decrease in AT and FII across
the adsorber might be interpreted as coagulation acti-
vation. Together with the decreased protamine to
heparin ratio, reflecting known heparin adsorption in
the HA device and the decrease FXII activity at the
end of CPB reflecting contact activation, our findings
further validate the need for therapeutic anticoagula-
tion associated with the procedure.
Conclusions
In patients at risk of post-operative complications, Cyto-
Sorb® haemoadsorption during cardiac surgery was not
associated with a decrease in cytokine levels or an im-
provement in relevant clinical outcomes. However, the
procedure appeared safe and feasible. In particular, a
thorough evaluation of coagulation profiles did not re-
veal any significant alterations in conventional haemato-
logical parameters or coagulation factors’ levels. Further
studies are required to evaluate CytoSorb® HA utilization
in situations associated with very high inflammatory re-
sponse or in established post-pump syndrome.
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patients included in the coagulation sub study. *There were no significant
differences between the groups with regard to any pre-operative or intra-
operative characteristics (all p values > 0.05) except for protamine/heparin
ratio (p = 0.02). †Chronic kidney disease was defined by a creatinine
clearance < 30ml/min. ‡Chronic heart failure was defined by a left
ventricular ejection fraction < 40%. CABG, coronary artery bypass grafting,
IQR interquartile range, SAPS II simplified acute physiology score, SD
standard deviation, ICU intensive care unit. Table S2. Outcomes of
patients included in the coagulation sub study. Table S3. Minimal detection
range of cytokines by the Luminex® Platform. Table S4. Haemoglobin,
platelets and coagulation tests. To be considered, pre-operative values, had
to be obtained within 24 h of the procedure. Post-operative values were
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